✦ LIBER ✦

High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial

✍ Scribed by Marshall R. Posner; James W. Darnowski; Alan B. Weitberg; Michael N. Dudley; Donna Corvese; Frank J. Cummings; Jefery Clark; Connie Murray; Neil Clendennin; Joseph Bigley; Paul Culabresi

Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 617 KB
Volume: 70
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19921215)70:12<2929::aid-cncr2820701233>3.0.co;2-w

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of 5-fluorouracil, leucovo

Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination

✍ Peter J. O'Dwyer; Mark J. Cornfeld; Ruth Peter; Robert L. Comis 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 492 KB

Dual modulation of 5-fluorouracil using

Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial

✍ J. Lokich; N. Anderson; M. Bern; F. Coco; T. Zipoli; C. Moore; L. Gonsalves 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 318 KB 👁 2 views

Oral hydroxyurea (HU) was added to a regimen of 5-fluorouracil(5-FU) plus leucovorin (LCV) administered as a continuous 24-hour infusion for 14 days. A previous report of the 5-FU plus LCV infusion established optimal dosages of 200 mg/mz/d and 5 mg/mz/d, respectively, for each agent. Oral HU was ad

Mitoxantrone, 5-fluorouracil, and high d

Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma : A randomized Phase II trial

✍ John D. Hainsworth; Jacques Jolivet; Robert Birch; Lisa G. Hopkins; F. Anthony G 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

Tenfour patients were treated with NFL: mitoxantrone 12 mg/m 2 IV on Day 1; leuconessee. vorin 300 mg IV over 30-60 minutes on Days 1, 2, and 3, immediately preceding

Phase I study of high dose 5-fluorouraci

Phase I study of high dose 5-fluorouracil and high dose leucovorin with low dose phosphonacetyl-l-aspartic acid in patients with advanced malignancies

✍ Bach Ardalan; Kasi Stridhar; Rajender Reddy; Pasquale Benedetto; Stephen Richman 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 416 KB

A phase I, II study of high-dose 5-fluor

A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies

✍ Bach Ardalan; Kasi S. Sridhar; Pasquale Benedetto; Stephen Richman; Stuart Waldm 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 454 KB 👁 3 views

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer